为探究 Tarlatamab 治疗经治小细胞肺癌（SCLC）的患者报告结局（PROs），研究发现其有积极效益风险比，意义重大。 小细胞肺癌（Small Cell Lung Cancer，SCLC）是肺癌中一种极具侵袭性的类型，就像隐藏在身体里的 “恶魔”，无情地侵蚀着患者的健康。它的 5 年总生存 ...

The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as Imdyllytra, for the treatment of small cell lung cancer that has spread ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.

The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...

Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority review. Tarlatamab has been ...